Data timelines which jump out from this announcement.
Azer-cel: Allogeneic CAR T cell therapy
- A preliminary early data update is anticipated in the second half of 2024
VAXINIA MAST Trial
- Bile tract cancer expansion trial opened and is expected to enroll approximately 10 patients; preliminary early data is expected in the second half 2024
OnCARlytics (CF33-CD19)
- Preliminary early combination data are expected in the fourth quarter of 2024
B Cell Immunotherapy: PD1-Vaxx
- Preliminary early data are expected in 2025
Good luck to all holders brave enough to have invested patient capital.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-23
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.001(1.04%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $172.8K | 3.557M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 72 | 7950851 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 2379300 | 23 |
View Market Depth
| Last trade - 13.46pm 04/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |